EUCOPE Member Spotlight: Q&A with Ferrer
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In October, we spoke with Óscar Perez, Chief Officer, Marketing, Pricing & Market Access and Business Development at Ferrer Internacional.
Óscar Perez has a degree in Pharmacy from the University of Barcelona, EMBA from ESADE and AMP from IESE. Óscar teaches and mentors entrepreneurship at ESADE, UPF and CESIF, of top of a regular mentorship task at EIT Health and other incubators. After various global and regional strategy and commercial executive positions at biopharmaceutical companies Amgen and Celgene, he joined Ferrer in 2018 to lead the creation of a global strategy department. He currently has responsibility for the corporate departments of Marketing, Pricing and Market Access, Business Analysis, Public Affairs & Patient Advocacy and Business Development.
Tell us about your organisation and its mission and how you drive innovation internally?
Ferrer is a well-respected Barcelona-based, family-owned and vertically integrated multinational pharma company with a growing focus on low prevalence, severe conditions within the areas of Pulmonary Vascular & Interstitial Lung Diseases and Neurological Disorders.
As a BCorp, we want to promote a new way of doing business and approaching the world. We want to be a positive impact company.
How do your organisation’s activities help patients now and into the future?
Ferrer focuses on two therapeutic areas to bring transformative products to underserved patients. We manage the entire value chain with our in-house capabilities and expertise, from all stages of development and manufacturing up to a comprehensive commercial approach to the different geographies, making sure that access to meaningful solutions in low-prevalence, severe or debilitating, medical specialty conditions, is successfully granted.
What do you see as the biggest challenge facing the life sciences industry today?
The increasing aging population and the immediate consequence of a higher prevalence of chronic conditions requires different healthcare strategies and models in which the pharmaceutical companies should become a key partner, a travel mate, getting more and more involved and committed to a holistic approach to disease management, beyond a mere pharmaceutical intervention.
What are the major health policy issues and themes that you are most focused on in 2022?
Healthcare budget measures for efficient management, timely access to innovation, support to public-private collaborations, holistic approach to chronic conditions from early stages for a better and more predictable outcome.
What attracted you to join EUCOPE and how can we help you achieve your business goals?
Sitting together with many sector-mates, listening to their experiences, sharing best practices, and being part of a lobby association aimed at making pharma innovation advance meaningfully for the best of the patients, is what made Ferrer want to be part of EUCOPE.